Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

2.

Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

Uribe P, Gonzalez S.

Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Review.

PMID:
21531084
3.

Epidermal growth factor receptor biology in head and neck cancer.

Kalyankrishna S, Grandis JR.

J Clin Oncol. 2006 Jun 10;24(17):2666-72. Review.

PMID:
16763281
4.

Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.

Kao J, Sikora AT, Fu S.

Curr Cancer Drug Targets. 2009 Dec;9(8):931-7. Review.

PMID:
20025602
5.

Cetuximab: from bench to bedside.

Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S.

Curr Cancer Drug Targets. 2010 Feb;10(1):80-95. Review.

PMID:
20088790
6.

EGFR-targeting monoclonal antibodies in head and neck cancer.

Astsaturov I, Cohen RB, Harari P.

Curr Cancer Drug Targets. 2007 Nov;7(7):650-65. Review.

PMID:
18045070
7.

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

Sundvall M, Karrila A, Nordberg J, Grénman R, Elenius K.

Expert Opin Emerg Drugs. 2010 Jun;15(2):185-201. doi: 10.1517/14728211003716442. Review.

PMID:
20415599
8.

Targeting epidermal growth factor receptor in head and neck cancer.

Ford AC, Grandis JR.

Head Neck. 2003 Jan;25(1):67-73. Review.

PMID:
12478546
9.

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.

Herbst RS, Kim ES, Harari PM.

Expert Opin Biol Ther. 2001 Jul;1(4):719-32. Review.

PMID:
11727507
10.
11.

Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.

Bozec A, Peyrade F, Milano G.

Anticancer Agents Med Chem. 2013 Mar;13(3):389-402. Review.

PMID:
23092267
12.
13.

The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma.

O-charoenrat P, Rhys-Evans PH, Modjtahedi H, Eccles SA.

Oral Oncol. 2002 Oct;38(7):627-40. Review.

PMID:
12167415
14.

Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer.

Lango MN, Shin DM, Grandis JR.

Curr Opin Oncol. 2001 May;13(3):168-75. Review.

PMID:
11307060
15.

Mechanisms of resistance to EGFR inhibitors in head and neck cancer.

Cooper JB, Cohen EE.

Head Neck. 2009 Aug;31(8):1086-94. doi: 10.1002/hed.21109. Review.

PMID:
19378324
16.

Epidermal growth factor receptor as a therapeutic target in head and neck cancer.

Bonner JA, De Los Santos J, Waksal HW, Needle MN, Trummel HQ, Raisch KP.

Semin Radiat Oncol. 2002 Jul;12(3 Suppl 2):11-20. Review.

PMID:
12174340
17.

Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.

Ang KK, Andratschke NH, Milas L.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):959-65. Review.

PMID:
14967456
18.
19.

Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature.

Rabinowits G, Haddad RI.

Oral Oncol. 2012 Nov;48(11):1085-9. doi: 10.1016/j.oraloncology.2012.06.016. Epub 2012 Jul 25. Review.

PMID:
22840785
20.

PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging.

van Dijk LK, Boerman OC, Kaanders JH, Bussink J.

Clin Cancer Res. 2015 Aug 15;21(16):3602-9. doi: 10.1158/1078-0432.CCR-15-0348. Epub 2015 Apr 30. Review.

Supplemental Content

Support Center